Pimicotinib shows 76% response rate and functional benefits in TGCT phase 3 trial

Dr. Randall discussed results from the phase 3 MANEUVER trial of the CSF-1 receptor inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT). The data were presented at the 2025 ESMO Congress.

The trial enrolled 63 patients and achieved an overall response rate of 76.2% as assessed by blinded independent review using RECIST 1.1 criteria. Safety findings were consistent with earlier reports, showing no new safety signals.

Patient-reported outcomes improved in a clinically meaningful way, indicating that the drug not only reduced tumor size but also enhanced joint function and quality of life. Dr. Randall emphasized the importance of these functional benefits.

These results suggest that pimicotinib could become a valuable treatment option for TGCT, a disease that currently has limited systemic therapies.